In what can only be regarded as a risky move, Valeant Pharmaceuticals International has licensed development and commercialisation rights to AstraZeneca's IL-17 (interleukin-17) receptor monoclonal antibodybrodalumab, which is expected to be filed for regulatory approval in moderate-to-severe psoriasis in the EU and the US inQ4 2015. The drug’s originator Amgen backed out of a co-development arrangement with AstraZeneca in May 2015 after events of suicidal ideation and behaviour were observed in the drug’s Phase III programme, which it believed would likely necessitate restrictive labelling.